The dual-targeting CAR T-cell therapy KITE-363 showed positive response rates and manageable side effects in relapsed or ...

Here we present an effective method for enhancing CAR transgene expression in γδ T cells using a Baboon-pseudotyped lentiviral vector (BaEV-LV), comparing ... was used to decrease non-specific binding ...

Blue Label has a non-controlling 49.5% stake in Cell C. (Photograph by Lesley Moyo) Blue Label Telecoms, the majority shareholder of Cell C, is mulling the possible listing of the mobile operator ...

Johannesburg - Blue Label Telecoms [JSE:BLU] has said that plans to acquire 35% of Cell C for R4bn as part of a recapitalisation plan are still “on track”. In December last year, the boards of Cell C ...

agreed to collaborate to advance the development and manufacturing of lentiviral-based gene and cell therapies. The goal is to offer biopharma and biotech clients with an end-to-end, optimized ...

Blue Label Telecoms, the majority shareholder of Cell C, is mulling the possible listing of the mobile operator on the Johannesburg Stock Exchange (JSE) as it restructures its business.

Not all DNA looks like the familiar twisted ladder. Sometimes, parts of our genetic code fold into unusual shapes. One such ...

A new study uncovers a surprising mechanism by which the SARS-CoV-2 virus, responsible for COVID-19, might cause ...

Headquartered in Hsinchu, Taiwan, tcmc is dedicated to producing high-quality CGT products. One of its key technologies is lentiviral vector (LVV) pr ...